The role of surface molecule CD229 in Multiple Myeloma.
CAR T cells
CD229
Diagnostic markers
Immunotherapy
Monoclonal antibody
Multiple Myeloma
SLAM family receptors
SLAMF3
Journal
Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
16
09
2018
revised:
12
10
2018
accepted:
12
10
2018
pubmed:
17
10
2018
medline:
31
3
2020
entrez:
17
10
2018
Statut:
ppublish
Résumé
The outcome of Multiple Myeloma (MM) patients has dramatically improved, however, most patients will still succumb to their disease. Additional therapeutic options are urgently needed and novel immunotherapies are enormously promising in the therapeutic armamentarium against MM. The first step in the development of any immunotherapy needs to be the identification of an appropriate target structure. In this review we present the current knowledge on surface molecule CD229, a member of the Signaling Lymphocyte Activation (SLAM) family of immune receptors. We believe that based on its characteristics, including (1) strong and homogenous expression on all myeloma cells, (2) expression on myeloma precursors, (3) absence from most normal tissues, (4) a central function in the biology of MM, CD229 (SLAMF3) represents a promising target for anti-MM immunotherapies. The introduction of novel anti-CD229 approaches into the clinic will hopefully lead to more durable responses, or maybe even cures, in MM.
Identifiants
pubmed: 30326256
pii: S1521-6616(18)30568-0
doi: 10.1016/j.clim.2018.10.006
pii:
doi:
Substances chimiques
LY9 protein, human
0
Signaling Lymphocytic Activation Molecule Family
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
69-73Informations de copyright
Copyright © 2018 Elsevier Inc. All rights reserved.